End of the day the 3b issues focus is because a lot of shareholders can't see the clear value delivered from Medcan and acquisition of 45% stake do not own of MCL. I don't care about shares on issue but market cap and what value delivered from extra shares issued. The market can't see the value either as they are not buying up....or more not easily clear to them....as lot of info in the 131 page report but is there a clear value proposition presented which succinctly starts with the bigger market opportunity, how QBL will leverage this, and timelines to achieve and how against relevant peer cannabis stocks provides superior value proposition. Yeh probably a lot of this in the 131 page document but that is not a clear investor proposition to work with.
Like I said I look forward to a clear and succinct investor presentation slide pack and perhaps even some independent research commissioned by QBL to highlight the value of the new QBL post acquisitions. More and more I see the need for the latter as producing voluminous documents or QBL media doco's are not really cutting it cf imho what a slick investor presentation and independent research report would do. Then again not saying the latter is the magic silver bullet, as probably need all those things. They really are trying it seems (QBL management) and given time they may get there as I can see glimpses that looks on surface a good deal and some plans but missing that clear succinct messaging that usually provided in investor presentations and/or independent research reports (noting no analyst coverage of QBL).
QBL Price at posting:
3.9¢ Sentiment: None Disclosure: Held
